Oncology
Hematologic Malignancy
2
Pipeline Programs↗
10
Active Trials↗
4
Companies Involved↗
Hematologic Malignancy is an early-stage landscape with 2 programs across 4 companies. The most active players are Cellerant Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
23
clinical trials
Completed8 · 35%
Recruiting8 · 35%
Terminated2 · 9%
Unknown status2 · 9%
Not yet recruiting2 · 9%
Withdrawn1 · 4%
Clinical Trials
Trial Activity
23 trials
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
Not yet recruiting·
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06211751·208 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06211751·208 enrolledPage 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)